Hederasaponin composition, hedera helix leaf extract comprising same and application of hederasaponin composition and hederasaponin extract

By optimizing the proportion of ivy saponin components, an ivy saponin composition with good anti-inflammatory effects was prepared, which solved the problems of unknown components of ivy leaf extracts and poor anti-inflammatory effects in the prior art, and achieved improvement of anti-inflammatory effects and Expanding application scope.

CN119074745APending Publication Date: 2024-12-06ZHEIJIANG CONBA CHINESE MEDICINE CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411192901.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

In the prior art, the components of ivy leaf extracts are unknown, have poor anti-inflammatory effects, and the medicinal ingredients of the extract are not fully enriched, resulting in high dependence on the source of medicinal materials and easy to affect production quality.

Method used

By screening and optimizing the proportion of ivy saponins, a composition including ivy saponins C, α-ivy saponins, ivy saponins B and ivy saponins D was prepared, with a mass ratio of (12-25): (5 -10):1:(1-2) to improve the anti-inflammatory effect and ensure that the total saponin content is no less than 70%, the total flavonoid content is no less than 4%, and the total polysaccharide content is no less than 2% in the extract. .

Benefits of technology

The anti-inflammatory effect has been improved, the technical bias of single ingredient improving the anti-inflammatory effect has been overcome, and the synergistic anti-inflammatory composition has been obtained, which has reduced the limitations of the source of medicinal materials and extraction process, expanded the scope of application, and has economic value and Industrial interests.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005015568930000061
    Figure BDA0005015568930000061
  • Figure BDA0005015568930000071
    Figure BDA0005015568930000071
  • Figure BDA0005015568930000081
    Figure BDA0005015568930000081
Patent Text Reader

Abstract

The invention discloses a hederin composition and a hederin leaf extract. The hederin composition comprises hederin C, alpha-hederin, hederin B and hederin D in a mass ratio of (12-25): (5-10): 1: (1-2). The hedera helix saponin composition and the hedera helix leaf extract can be used for preparing drugs for treating or preventing acute bronchitis and drugs for eliminating phlegm and relieving cough. The hederasaponin composition and the hederasaponin extract are definite in component and better in anti-inflammatory effect, the four components are in synergistic interaction, the anti-inflammatory effect better than that of a single component is achieved, the technical prejudice that the drug effect of the whole composition is improved by improving the content of the component with the highest anti-inflammatory effect is overcome, and unexpected technical effects are generated. The extract provided by the invention is not limited by medicinal material sources and extraction processes, and for the extracts with different component contents, the component contents of the extracts can be adjusted to be increased or decreased, so that the saponin composition with the ratio provided by the invention is obtained, and the extract also can achieve a relatively good anti-inflammatory effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of traditional Chinese medicine, and in particular to an ivy saponin composition, an ivy leaf extract comprising the composition and applications thereof. Background Art

[0002] The ethanol extract of Hedera helix has multiple effects such as antispasmodic, mucolytic, anti-inflammatory, antibacterial and antiviral. Hedera helix preparations are currently on the market in many countries around the world and are widely used for respiratory diseases such as respiratory mucositis, chronic bronchitis, and acute respiratory inflammation with cough. At present, the ethanol extract of Hedera helix is ​​used as an expectorant and is made into tablets, capsules, effervescent tablets, oral liquids and other dosage forms, and is approved for marketing in many countries including Europe. As a botanical medicine, Hedera helix preparations have good safety and tolerability in children. The currently listed Prospan brand Hedera helix leaf extract syrup contains 7 mg / mL of Hedera helix leaf extract extracted with 30% ethanol, 1.34 mg of potassium sorbate, 500 μg of anhydrous citric acid, 550 mg of sorbitol, 1.5 mg of xanthan gum, 3 mg of essence, and pure water to 1 mL. Among them, the Hedera helix leaf extract is a crude extraction of 30% ethanol, and the content of saponins and other active ingredients is low.

[0003] The main active substances in Hedera helix are saponins. The disaccharide glycosides of triterpenoid saponins include hedera helix saponin B, hedera helix saponin C, hedera helix saponin D, and the monosaccharide glycoside α-hedera helix saponin. Other ingredients include flavonoids, coumarins, polyacetylenes, phenolic acids, alkaloids, volatile oils, etc. However, Prospan brand Hedera helix leaf extract is a 30% ethanol crude extract, and its active ingredients are not clear; the effective ingredients are not fully enriched, and the amount of extract taken is large; the unknown ingredients are not conducive to quality control. Moreover, the Hedera helix leaf extract obtained by the current preparation method is highly dependent on the germplasm resources of Hedera helix leaves, and the production of the extract and the quality of the product are easily affected by the medicinal resources.

[0004] The prior art discloses a method for preparing an extract containing hedera hedera saponin.

[0005] CN1856317A discloses a method for preparing an ivy leaf extract and an extract prepared by the method (application date: 2004.09.10; publication date: 2006.11.01), wherein the technology adopts a) the first α-hederin-rich extract is provided by fermenting crushed ivy leaves with water to convert hederacoside C into α-hederin, which contains at least 3% α-hederin; b) the second hederacoside C-rich extract is provided by treating crushed ivy leaves with superheated steam to inhibit the conversion of hederacoside C into α-hederin, which contains at least 5% hederacoside C; c) the first and second extracts are mixed to obtain an extract containing an adjusted hederacoside C content and an adjusted α-hederin content. The technical solution solves the problem of enriching hederacoside C and α-hederacoside, and other medicinal ingredients and anti-inflammatory activity are not disclosed.

[0006] The one-test-multiple-evaluation method for determining the four main saponin components in helix helix and its extracts (Journal of Drug Analysis 2018, 38(06), 986-996) discloses a method for preparing helix helix leaf extract: weigh an appropriate amount of dried helix helix leaves and crush them into coarse powder, extract them twice with 80% ethanol water at 85-90°C, add 9 times the amount for the first time and reflux for 1h, add 5 times the amount for the second time and reflux for 0.5h, filter, combine the filtrate, recover the ethanol until there is no alcohol taste, dissolve it with 6 times the amount of water, let it stand at 4°C overnight, filter, pass it through a DM130 macroporous adsorption resin column, elute with water until it is colorless, then elute with 3 times the amount of 30% and 3 times the amount of 70% ethanol water, collect the 70% ethanol water eluate, concentrate the filtrate, dry, and crush to obtain. The content of hedera saponin C in the ivy leaf extract is up to 66%, the content of hedera saponin D is up to 7%, the content of hedera saponin B is up to 3%, the content of α-hedera saponin is up to 22%, and the total content of the four saponins is up to 80%. However, this technical solution aims to enrich saponins, and does not disclose the anti-inflammatory effect and other medicinal ingredients.

[0007] The one-test-multiple-evaluation method was used to simultaneously determine four saponins in ivy oral liquid (Chinese Patent Medicine, Vol. 40, No. 8, 2018). The extract was extracted with 80% ethanol, treated with alkali solution, and allowed to stand overnight at 4°C. The filtrate was passed through a DM130 macroporous resin column and gradient eluted with 30% ethanol and 70% ethanol. The 70% ethanol eluate was collected and concentrated to obtain the extract. However, the composition, content and anti-inflammatory effect of the extract were not disclosed.

[0008] The abstract of the optimization of the preparation process of Hedera helix extract (Yang Ziwen, 2018) states: 80% ethanol extraction, 1% alkali treatment of the medicinal material, cold precipitation at 4°C for 8h, the filtrate is passed through an HPD-100 macroporous resin column, gradient eluted with 30% ethanol and 80% ethanol, the 80% ethanol eluate is collected, and the extract is obtained after concentration. The average content of hedera helix saponin C in the extract is 40.44%, the average content of α-hedera helix saponin is 17.09%, the recovery rate is 65.24%, and the sum of the content of hedera helix saponin C and α-hedera helix saponin can reach 57.52%. However, the other components and contents of the extract and the anti-inflammatory effect are not disclosed.

[0009] CN104306416A discloses a drug for treating bronchitis, pneumonia and asthma and its preparation method (publication date: 2015-01-28), wherein the preparation method of ivy saponin components is recorded: weigh the stems and leaves of ivy, reflux extract with 10-90% ethanol solution in an extraction kettle according to the mass volume ratio of ivy stems and leaves to ethanol solution of 1:3-10, filter after reflux extraction, centrifuge, concentrate under reduced pressure, and evaporate to extract; dissolve with deionized water, pass through a macroporous resin column, and elute with water and ethanol solution in turn; concentrate the ethanol eluate under reduced pressure, dry under vacuum at 60°C, weigh, and obtain ivy saponin. The specification discloses the effect of ivy oral liquid made of ivy saponin and ivy volatile oil on the SOD activity in serum, lung tissue and BALF of rats with chronic bronchitis, but does not disclose the anti-inflammatory effect of saponin components.

[0010] CN102188465A discloses a preparation method and use of an ivy plant extract (publication date: 2011-09-21), wherein the ivy extract is extracted with an extraction solvent, the extract is subjected to a macroporous adsorption resin, and the alcohol eluent is dried to obtain an extract, and the total saponin content in the extract is not less than 30%. The extract can be used alone or in combination with other extracts to prepare drugs for treating rheumatoid arthritis, respiratory diseases, hepatitis, etc. However, the specification only uses the enrichment of total saponin content as a condition optimization target, and does not disclose the relationship between total saponins, saponin C and α-saponin and drug efficacy.

[0011] In the prior art, the extraction of ivy mainly focuses on increasing the content and recovery rate of saponins. For example, the use of 30% ethanol + 70% ethanol gradient elution is to remove impurities with high polarity, such as polysaccharides, pigments, etc., in order to enrich saponins in ivy extracts and increase the content of saponins. However, the prior art has not studied whether the anti-inflammatory efficacy of the extract is related to the saponin content or the specific ratio of components. From the perspective of common knowledge, the higher the saponin content, the better the efficacy, or the higher the content of a certain component, the better the anti-inflammatory effect. However, the applicant has found through research that there may be a phenomenon that is contrary to common knowledge. The prior art has not studied the content and proportion of saponin components in the extract, nor has it established a connection with the relationship between the anti-inflammatory efficacy. It is necessary to further optimize the saponin content ratio in the extract from the perspective of improving the anti-inflammatory efficacy of ivy extracts. Summary of the invention

[0012] The purpose of the present invention is to solve the technical problems in the prior art that the ivy leaf extract has unknown components and poor anti-inflammatory effect.

[0013] The present invention provides an ivy saponin composition with defined ingredients and better anti-inflammatory effect. The present invention screens and optimizes the proportion of saponin ingredients, and the ingredients of the composition synergize to enhance the effect, thereby improving the anti-inflammatory effect of the composition. The composition is not limited by the source of medicinal materials and the extraction process. Extracts with different ingredient contents obtained through medicinal materials from different sources and processes can be adjusted to increase or decrease the ingredient content of the extract to obtain the saponin composition with the proportion of the present invention, which can also achieve better anti-inflammatory effect.

[0014] The technical solution adopted by the present invention is:

[0015] A hedera saponin composition comprises hedera saponin C, α-hedera saponin, hedera saponin B and hedera saponin D, wherein the mass ratio of hedera saponin C, α-hedera saponin, hedera saponin B and hedera saponin D is (12-25):(5-10):1:(1-2).

[0016] Preferably, the mass ratio of hederacoside C to hederacoside D is (8-16):1.

[0017] More preferably, the mass ratio of hederacoside C, α-hederacoside, hederacoside B and hederacoside D is (16-25):(5-7):1:(1-2).

[0018] Alternatively, preferably, the mass ratio of the hederacoside C, α-hederacoside, hederacoside B and hederacoside D is (12-16):(7-10):1:1.

[0019] The present invention also provides an ivy leaf extract, which comprises hederacoside C, α-hederacoside, hederacoside B and hederacoside D, wherein the mass ratio of hederacoside C, α-hederacoside, hederacoside B and hederacoside D is (12-25):(5-10):1:(1-2), and in the extract, the content of hederacoside C is not less than 25%, the content of total flavonoids is not less than 4%, the content of total polysaccharides is not less than 2%, and the content of total saponins in the ivy leaf extract is not less than 70%.

[0020] Preferably, in the extract, the mass ratio of hederacoside C, α-hederacoside, hederacoside B and hederacoside D is (12-21):(5-9):1:(1-1.6).

[0021] More preferably, in the extract, the mass ratio of hederacoside C, α-hederacoside, hederacoside B and hederacoside D is (12-21):(5-6):1:(1-1.6).

[0022] More preferably, in the extract, the mass ratio of hederacoside C, α-hederacoside, hederacoside B and hederacoside D is (12-17):(6-9):1:(1-1.4).

[0023] More preferably, in the extract, the mass ratio of hederacoside C, α-hederacoside, hederacoside B and hederacoside D is (17-20):(5-9):1:(1.4-1.6).

[0024] Furthermore, in the extract, the content of α-hedera saponin is not less than 10%.

[0025] Furthermore, in the extract, the content of hederacoside C is not less than 30%, the content of hederacoside D is not less than 2%, and the content of hederacoside B is not less than 2%.

[0026] Preferably, the ivy leaf extract comprises organic acid compounds, flavonoid compounds, saponin compounds, glycoside compounds and other compounds, wherein the organic acid compounds comprise one or more of quinic acid, neochlorogenic acid, cryptochlorogenic acid, asiatic acid, madecassic acid, 3-O-sulfated echinocystic acid and 3-O-sulfated oleanolic acid;

[0027] The flavonoid compound includes one or both of isoquercetin and nicotinic acid glycoside;

[0028] The glycoside compound includes one or more of 3-O-β-D-pyranoglucopyranoside butyrate ethyl ester, (E)-4-O-β-D-pyranoglucopyranosyl-p-coumaric acid, 3-methylbut-2-enyl[β-D-furanoseyl-(1→6)]-β-D-pyranoglucopyranoside, epimedin F2, myresculoside, cincalciferol B19-O-β-D-pyranoglucopyranoside, and nomiline 17-β-D-pyranoglucopyranoside;

[0029] The saponin compound includes one or two of β-hedera saponin and cyperus saponin A;

[0030] The other compounds include one or more of 1-O-galloylglycerol, salidroside D, 3-methoxy-4-hydroxyphenol 1-O-[β-D-furanose syl-(1→6)]-β-D-pyranoglucoside, icariin B5, cinnamon acid H and cimicifuga epoxyglycoside.

[0031] Preferably, the ivy leaf extract includes α-hedera saponin, hedera saponin B, hedera saponin C and hedera saponin D, and one or more of the following compounds: quinic acid, neochlorogenic acid, cryptochlorogenic acid, asiatic acid, madecassic acid, 3-O-sulfated echinococcal acid, 3-O-sulfated oleanolic acid, 3-O-β-D-pyranoglucopyranoside butyrate ethyl ester, (E)-4-O-β-D-pyranoglucopyranosyl-p-coumaric acid, Myresculoside, β-hedera saponin, salidroside A, salidroside D, 3-methoxy-4-hydroxyphenol 1-O-[β-D-furanosyl-(1→6)]-β-D-pyranoglucopyranoside, camphor acid H, and cimicifuga epoxyglycoside.

[0032] More preferably, the ivy leaf extract includes chlorogenic acid, shikimic acid, 3-O-p-coumaroylquinic acid, nicotinic acid, esculin, α-hederaponin, hederaponin B, hederaponin C and hederaponin D.

[0033] The present invention also provides application of the ivy saponin composition or the ivy leaf extract in preparing a drug for treating or preventing acute bronchitis.

[0034] The present invention also provides application of the ivy saponin composition or the ivy leaf extract in preparing expectorant and antitussive drugs.

[0035] The present invention also provides a medicine for treating or preventing acute bronchitis, comprising the ivy saponin composition or the ivy leaf extract.

[0036] The present invention also provides an expectorant and antitussive medicine, comprising the ivy saponin composition or the ivy leaf extract.

[0037] The beneficial effects of the present invention are:

[0038] The present invention screens and optimizes the content ratios of the four components in ivy saponins, obtains an ivy saponin composition with a certain component and better anti-inflammatory effect, and solves the problem of limited sources of medicinal materials. The four components in the composition of the present invention work synergistically to achieve better anti-inflammatory effects than a single component. Conventional technology believes that if a single component has a good anti-inflammatory effect, increasing the content of the component will increase the anti-inflammatory effect of the composition accordingly. For example, in the present invention, among the four components of the composition, the order of anti-inflammatory activity from large to small is ivy saponin C>α-ivy saponin>ivy saponin B>ivy saponin D. According to conventional understanding, increasing the content of ivy saponin C and α-ivy saponin should have a better anti-inflammatory effect than increasing the content of ivy saponin B and ivy saponin D. However, the experimental results of the present invention prove that under the same weight gain, the anti-inflammatory effect of the composition obtained by increasing the content of ivy saponin B and ivy saponin D is better than the anti-inflammatory effect of the composition with increased content of ivy saponin C and α-ivy saponin. This is contrary to conventional understanding. This proves that there is a synergistic effect between the components of the composition of the present invention, and the anti-inflammatory effect of the four components is better at a specific content ratio, which overcomes the technical bias of improving the efficacy of the overall composition by simply increasing the content of the component with the highest anti-inflammatory effect, and produces unexpected technical effects.

[0039] The present invention also provides an ivy leaf extract with a defined composition and better anti-inflammatory effect, which is more conducive to reducing the dosage of patients and improving patient compliance; the extract of the present invention is not limited by the source of medicinal materials and the extraction process, and different sources of medicinal materials or different extraction processes obtain extracts with different component contents. According to the scheme of the present invention, the extract can be adjusted to increase or decrease the content of the components to obtain the saponin composition of the present invention, and such an extract can also achieve a good anti-inflammatory effect. The composition of the present invention has a wide range of applications and has great economic value and industrial benefits. DETAILED DESCRIPTION

[0040] The technical solution of the present invention is further described below with reference to specific embodiments, but the protection scope of the present invention is not limited thereto.

[0041] Example 1: Screening of anti-inflammatory activity of ivy saponins

[0042] 1. Test process

[0043] 1.1 Drugs and reagents

[0044] COX-2 inhibitor screening kit (Biyuntian Biotechnology), α-hedera saponin (China Food and Drug Inspection Institute), hedera saponin B / D (Chengdu Pufeide Biotechnology Co., Ltd.), hedera saponin C (self-made by Zhejiang Kangenbei Pharmaceutical Research and Development Center), DMSO (Diamond).

[0045] 1.2 Test methods

[0046] According to the test requirements of the kit, the drug administration group was set at a concentration of 100 μg / mL, a positive drug group (celecoxib), and a DMSO group. According to the instructions of the kit, a 100% enzyme activity control group, a blank control group, a positive inhibitor group, and a sample group were set up respectively. After adding the sample ivy saponin to be tested to the sample group well plate, mix it well and incubate it at 37°C for 10 minutes. 5 μL of COX-2Probe was added to each well of each group, and then 5 μL of COX-2Substrate working solution was quickly added to each well, mixed well, and incubated at 37°C in the dark for 5 minutes before fluorescence determination. The detection was carried out on a multifunctional microplate reader (Tecan), and the detection conditions were an excitation wavelength of 560 nm and an emission wavelength of 590 nm.

[0047] Inhibition rate (%) = (RFU 100%酶活性对照 -RFU 样品 ) / (RFU 100%酶活性对照 -RFU 空白对照 )×100%.

[0048] 2. Test results

[0049] Table 1 Inhibitory activity of ivy saponin monomer compounds on COX-2 enzyme

[0050]

[0051] The results showed that the ivy saponins had different COX-2 enzyme inhibitory activities and different anti-inflammatory effects. The order of anti-inflammatory activity of the four ivy saponins was ivy saponin C>α-ivy saponin>ivy saponin B>ivy saponin D.

[0052] Example 2: Screening of anti-inflammatory activity of ivy saponin composition

[0053] 1. Test process

[0054] 1.1 Preparation of samples to be tested

[0055] The ivy saponins in Example 1 were dissolved in methanol to prepare mother solutions of different concentrations, wherein the concentration of ivy saponin C was 0.3967 mg / ml, the concentration of α-ivy saponin was 0.4168 mg / ml, the concentration of ivy saponin B was 0.4812 mg / ml, and the concentration of ivy saponin D was 0.5182 mg / ml. Methanol was added to prepare the samples to be tested with a concentration of 100 μg / ml, and the samples to be tested were prepared according to Table 2 below.

[0056] Table 2 Ivy saponin composition preparation

[0057]

[0058] 1.2 Test methods

[0059] The COX-2 enzyme inhibition activity test was carried out according to the method of Example 1, and the inhibition rates of different samples to be tested were counted.

[0060] 2. Test results

[0061] The test results are shown in Table 3. Different compositions are composed of 4 kinds of ivy saponins, and the corresponding inhibition rates are different. Combining Tables 2 and 3, it can be seen that compared with composition 1, composition 2 adds 1 part of ivy saponin C and 1 part of α-ivy saponin, and the corresponding ivy saponin C content is reduced from 54.5% to 54.2%, and the corresponding α-ivy saponin content is increased from 45.5% to 45.8%. However, the anti-inflammatory activity of ivy saponin C and α-ivy saponin is similar, and the corresponding anti-inflammatory activity of composition 1 and composition 2 is not much different. Composition 3 adds 1 part of ivy saponin B and 1 part of ivy saponin D on the basis of composition 1, and the total number of compositions is the same as composition 2. The content of ivy saponin C is reduced from 54.2% of composition 2 to 50%; the content of α-ivy saponin is reduced from 45.8% to 41.6%; at the same time, the content of ivy saponin B and ivy saponin D is increased. The inhibition rate comparison showed that the inhibition rate of composition 3 was 58.26%, which was significantly higher than the inhibition rate of composition 2, which was 41.15%.

[0062] Similarly, in compositions 4-6, composition 5 has 2 parts of hederacoside C and 1 part of α-hederacoside added to composition 4, respectively. In the corresponding monomer component ratio in the mixture, the content of hederacoside C decreases, and the content of α-hederacoside increases, but the inhibition rate does not change significantly compared with composition 4; composition 6 adds 1 part of hederacoside B and 2 parts of hederacoside D on the basis of composition 4, and the total number of compositions is the same as composition 5, but the content of hederacoside C and α-hederacoside in composition 6 is reduced. The inhibition rate comparison shows that the inhibition rate of composition 6 is 60.73%, which is higher than the inhibition rate of composition 5 of 55.62%.

[0063] Among compositions 7-9, composition 8 adds 2 parts of hederacoside C compared with composition 7, thereby increasing the content ratio of saponin C in the mixture monomer. At the same dosage concentration, the inhibition rate of composition 8 is 57.96%, which is better than the inhibition rate of composition 7 of 49.30%. Composition 9 adds 1 part of hederacoside B and 1 part of hederacoside D compared with composition 7, and the number of hederacoside C remains unchanged, which is equivalent to replacing 2 parts of hederacoside C in composition 8 with 1 part of hederacoside B and 1 part of hederacoside D, but the corresponding inhibition rate of composition 9 is 61.19%, which is higher than composition 8.

[0064] Combined with the inhibition rate of the monomer compounds in Table 1, it can be seen that the inhibition rates of ivy saponin C and α-ivy saponin are higher than those of ivy saponin B and ivy saponin D. Compositions 3, 6 and 9 respectively improve the efficacy of the compositions by adding ivy saponin B and ivy saponin D with lower inhibition rate activity, replacing the efficacy contribution of ivy C and α-ivy saponin, and even obtaining better efficacy, producing unexpected technical effects.

[0065] Compositions 10-11 were set up with 4 kinds of ivy saponins at a ratio of 1:1:1:1 and compared with a composition of ivy saponin C and α-ivy saponin 3:1. The test results showed that the inhibition rates of compositions 10 and 11 were 41.40% and 49.01%, respectively, which were lower than compositions 3, 6 and 9 at the same dosage concentration. Moreover, composition 10 used ivy saponin B and ivy saponin D to replace an equal amount of ivy saponin C, and the corresponding inhibition rate did not increase.

[0066] Therefore, when hederacoside C and α-hederacoside are used in combination with hederacosides B and D, the anti-inflammatory effect of the composition may not be increased. The four saponins in the composition need to be in the ratio of hederacoside C: α-hederacoside: hederacoside B: hederacoside D = (12-25): (5-10): 1: (1-2) to achieve the technical effect of synergistic enhancement.

[0067] Table 3 Inhibitory activity of ivy saponin composition on COX-2 enzyme

[0068]

[0069] The applicant further studied the components of the ivy leaf extract and found that hederacoside C, α-hederacoside, hederacoside B and hederacoside D are important medicinal ingredients of the ivy leaf extract. At the same time, the ratio of the components in the ivy leaf extract was compared with the ratio of the components in the composition of Example 2. It was found that when the ratio of saponins in the extract was within the ratio range of the above composition, the ivy leaf extract also had a good anti-inflammatory effect. The following preparations of different extracts were carried out using Hedera helix as a raw material. Among them, the production batch numbers of Hedera helix medicinal materials are Z226b-210602, Z226b-210502, LX220501, and LX220502.

[0070] Example 3: Preparation of Extract 1

[0071] Weigh 200g of dried ivy leaves of production batch number Z226b-210602, crush them into coarse powder, extract them twice with 80% ethanol in an amount of 12 times the volume of the medicinal material, the extraction temperature is 80-90°C, filter and combine the filtrate, recover the ethanol until there is no alcohol taste, add 60ml (0.3 times the feed amount) of 5% sodium hydroxide solution, add water to a total volume of 12 times the feed amount, adjust the pH to 9.5-11, refrigerate (0-4°C) and stand overnight, filter, pass through HPD100 macroporous adsorption resin, elute with water until colorless, then elute with 70% ethanol in an amount of 3 times the column volume, collect the 70% ethanol eluate, concentrate the filtrate, dry, and crush to obtain.

[0072] Example 4: Preparation of Extract 2

[0073] Weigh 200g of dried ivy leaves of the production batch number of Ivy Hedera helix Z226b-210502, crush them into coarse powder, reflux extract twice with 85% ethanol in an amount of 9 times the volume of the medicinal material, the extraction temperature is 80-90°C, filter and combine the filtrate, recover the ethanol until there is no alcohol taste, add 0.4 times the feed amount of 5% sodium hydroxide solution, add water to the total volume of 9 times the feed amount, adjust the pH to 9.5-11, refrigerate and stand overnight, filter, adsorb the filtrate through the macroporous resin of HPD100, elute with water until colorless, then elute with 60% ethanol in an amount of 5 times the column volume, collect the 60% ethanol eluate, concentrate, dry, and crush to obtain.

[0074] Example 5: Preparation of Extract 3

[0075] Weigh 200g of dried ivy leaves of the production batch number of LX220501 of the ivy medicinal material, crush them into coarse powder, reflux extract twice with 80% ethanol in an amount of 12 times the volume of the medicinal material, the extraction temperature is 80-90°C, filter and combine the filtrate, recover the ethanol until there is no alcohol taste, use potassium hydroxide solution, add water to a total volume of 12 times the feed amount, adjust the pH to 9.5-11, refrigerate and stand overnight, filter, adjust the pH of the filtrate to neutral, pass the filtrate through a polyamide column (30-60 mesh), elute with water until colorless, then elute with 70% ethanol in an amount of 3 times the column volume, collect the 70% ethanol eluate, concentrate the filtrate, dry, and crush to obtain.

[0076] Example 6: Preparation of extract from control group 1

[0077] Based on Example 3, the alkali solution was adjusted to 1% of the medicinal material amount, a DM130 chromatographic column was used, and 30% ethanol was added for elution, as follows:

[0078] Weigh 200g of dried ivy leaves of production batch number Z226b-210602, crush them into coarse powder, extract them twice with 80% ethanol in an amount of 12 times the volume of the medicinal material, the extraction temperature is 80-90°C, filter and combine the filtrate, recover the ethanol until there is no alcohol taste, add 0.2 times the feed amount of 5% NaOH solution, add water to the total volume of 12 times the feed amount, adjust the pH to 9.5-11, refrigerate and stand overnight, filter, pass through DM130 macroporous adsorption resin, elute with water until colorless, then elute with 3 times the column volume of 30% ethanol, and then elute with 3 times the column volume of 70% ethanol, collect the 70% ethanol eluate, concentrate the filtrate, dry, and crush to obtain.

[0079] Example 7: Preparation of extract from control group 2

[0080] The extract of control group 2 was prepared according to the preparation method of "One test and multiple evaluation method for determination of four main saponin components in Hedera helix and its extracts" (Journal of Drug Analysis 2018, 38(06), 986-996):

[0081] Weigh 200 g of dried ivy leaves of production batch number LX220502 of the ivy medicinal material, crush them into coarse powder, reflux extract twice with 80% ethanol water with 12 times the volume of the medicinal material at 85-90°C, add 9 times the amount of ethanol water for the first time and reflux for 1h, add 5 times the amount for the second time and reflux for 0.5h, filter, combine the filtrate, recover ethanol until there is no alcohol taste, dissolve it with 6 times the amount of water, let it stand at 4°C overnight, filter, pass through a DM130 macroporous adsorption resin column, elute with water until colorless, then elute with 3 times the amount of 30% and 3 times the amount of 70% ethanol water, collect the 70% ethanol water eluate, concentrate the filtrate, dry, and crush to obtain.

[0082] Example 8: Preparation of extract from control group 3

[0083] Weigh 200g of dried ivy leaves of the production batch number of LX220501 of the ivy medicinal material, grind them into coarse powder, reflux extract twice with 80% ethanol in an amount of 12 times the volume of the medicinal material, the extraction temperature is 80-90°C, filter and combine the filtrate, recover the ethanol until there is no alcohol taste, add 0.3 times the feed amount of 5% sodium hydroxide solution, add water to the total volume of 12 times the feed amount, adjust the pH to 9.5-11, refrigerate and stand overnight, filter, adsorb with 5 times the feed amount of alkaline alumina, elute with 3 times the column volume of water, collect the water washing liquid, concentrate, dry, add an appropriate amount of methanol for ultrasonic extraction, filter, and concentrate and dry the filtrate.

[0084] Example 9: Component Detection

[0085] 1. Test methods

[0086] 1.14 Methods for determining the content of ivy saponins

[0087] Preparation of reference solution: Take appropriate amount of Hederacoside C reference and α-hederacoside reference, weigh accurately, and add methanol to prepare a mixed solution containing 0.5 mg of Hederacoside C and 0.2 mg of α-hederacoside per 1 ml. Take appropriate amount of Hederacoside B and Hederacoside D reference, add methanol to prepare a solution containing 0.5 mg of Hederacoside B per 1 ml and a solution containing 0.5 mg of Hederacoside D per 1 ml, respectively.

[0088] Preparation of test solution: Take 50 mg of ivy leaf extract, accurately weigh it, put it in a 50 ml volumetric flask, add 80% methanol to dissolve it by ultrasonic and dilute it to the scale, shake it well, filter it, and take the filtrate to obtain the solution.

[0089] Chromatographic conditions and system suitability test: chromatographic column ZORBAX Eclipse XDB-C18 Analytical (4.6*250mm 5-Micron); acetonitrile as mobile phase A, 0.05% phosphoric acid solution as mobile phase B, gradient elution as specified in Table 4; column temperature 25°C; detection wavelength 205nm; injection volume 10μl, flow rate 1.0ml per minute.

[0090] Table 4 Liquid phase elution gradient

[0091]

[0092] Determination method: Accurately pipette 10 μl of reference solution and test solution respectively, inject into liquid chromatograph, and determine.

[0093] 1.2 Determination of total saponin content

[0094] Preparation of reference solution: Take an appropriate amount of ivy saponin C, weigh it accurately, and add methanol to make a solution containing 0.4 mg per 1 ml.

[0095] Preparation of standard curve: Accurately measure 0.1ml, 0.2ml, 0.3ml, 0.4ml and 0.5ml of reference solution, place in stoppered test tubes respectively, evaporate in a water bath, accurately add 5ml of perchloric acid to each tube, shake well, react in a 70℃ water bath for 15 minutes, take out, cool in an ice bath for 5 minutes, take out, shake well, use the corresponding reagent as blank, and detect at detection wavelengths of 322nm and 406nm according to the UV-Vis spectrophotometry (General Rule 0401), draw a standard curve with absorbance as the ordinate and concentration as the abscissa.

[0096] Preparation of test solution: Take 50 mg of ivy leaf extract, accurately weigh it, put it in a stoppered conical flask, add 50 ml of water, dissolve it by ultrasonic, take it out, extract it twice with a water-saturated n-butanol solution, 100 ml each time, combine the n-butanol layers, recover to dryness under reduced pressure, dissolve the residue in methanol and make up to the volume in a 50 ml volumetric flask, shake well, and obtain it.

[0097] Determination method: Accurately measure 0.1 ml of the test solution, place it in a stoppered test tube, evaporate it in a water bath, and follow the method under the preparation of the standard curve, starting from "accurately add 5 ml of perchloric acid", determine the absorbance according to the law, read the weight of hederaconin C in the test solution, and calculate it from the standard curve.

[0098] 1.3 Determination of total flavonoid content

[0099] Preparation of test solution: Take 0.5 g of ivy leaf extract, accurately weigh it, put it into a 100 ml volumetric flask, add 70% ethanol, dissolve it by ultrasonication and dilute it to the scale line, shake well, and obtain the solution.

[0100] Preparation of standard curve: Accurately measure 0.2ml, 0.6ml and 1.0ml of rutin control solution and place them in 10ml volumetric flasks respectively. Add water to 3ml each, accurately add 2ml of acetic acid-sodium acetate buffer (pH4.5) and 0.1mol / L aluminum chloride solution, shake well, add 70% ethanol to the scale, shake well, use the corresponding reagent as blank, scan the full wavelength at 200-600nm according to the UV-Vis spectrophotometry (Appendix VA), measure the spectrum, select the maximum absorption wavelength for detection, and draw the standard curve with absorbance as the ordinate and concentration as the abscissa.

[0101] Determination method: Accurately measure 0.5 ml of the test solution and place it in a 10 ml volumetric flask. According to the method under the standard curve preparation, starting from "add water to 3 ml", determine the absorbance according to the law, read the amount of rutin in the test solution, and calculate it from the standard curve.

[0102] 1.4 Determination of total polysaccharide content

[0103] Preparation of test solution: Take 0.5 g of ivy leaf extract, add 5 ml of 25% methanol and dissolve by ultrasonication, pass through an ODS column (2 cm*25 cm), elute with 25% methanol, collect 2 times the column volume of eluate (150 ml), and discard the rest.

[0104] Preparation of standard curve: Accurately measure 0.0ml, 0.2ml, 0.6ml, 0.8ml and 1.0ml of glucose control solution and place them in 20ml stoppered test tube bottles respectively. Add water to make up to 1ml each, accurately add 1ml of 5% phenol solution, shake well, then add 5ml of sulfuric acid, shake well, heat in a 100℃ water bath for 20min, take out, cool in an ice bath for 5min, let stand for 20 minutes, measure the absorbance at a wavelength of 488nm, and draw a standard curve with absorbance and concentration.

[0105] Determination method: Accurately measure 0.5 ml of the test solution and place it in a 20 ml volumetric flask. According to the method under the standard curve preparation, starting from "add water to 1 ml", determine the absorbance according to the law, read the amount of glucose in the test solution from the standard curve, and calculate it.

[0106] 2. Test results

[0107] The results of component determination of ivy leaf extracts 1-3 and control group 1-3 showed that the ratio of hederacoside C: α-hederacoside: hederacoside B: hederacoside D of extract 1-3 was (12-21): (5-9): 1: (1-1.6), which was consistent with the ratio of hederacoside C: α-hederacoside: hederacoside B: hederacoside D = (12-25): (5-10): 1: (1-2). However, the saponin content ratio of control group 1-3 was not within the above range, among which the D / B content ratio (0.78) of control 1, the α / B content ratio (3.21) of control group 2 and the C / B content ratio (11.00) of control group 3 were significantly lower than the composition range.

[0108] Table 5 Parameters of different ivy leaf extracts

[0109]

[0110]

[0111] Example 10: Extract efficacy test

[0112] 1. Experimental process

[0113] 1.1 Preparation of samples to be tested

[0114] (1) Preparation of test samples: Ivy leaf extracts 1-3 and control groups 1-3 were added with methanol to prepare test samples with a final concentration of 50 μg / ml.

[0115] (2) Preparation of spiked reference substance: According to the extraction content determination results of Example 9, different amounts of saponin content were added to control groups 1 and 3, and the content was determined using the method of Example 9, so that the obtained extract had a saponin ratio corresponding to the composition.

[0116] Table 6 Preparation of spiked control group

[0117]

[0118] Table 7 Parameters of the spiked control group extract

[0119]

[0120] 1.2 Test methods

[0121] The COX-2 enzyme inhibition activity test was carried out according to the method of Example 1, and the inhibition rates of different samples to be tested were counted.

[0122] 2. Test results

[0123] The test results are shown in Table 8. The saponin content ratios of extracts 1-3 and spiked control 1 are all within the range of the composition of Example 2, that is, they meet the ratio of ivy saponin C: α-ivy saponin: ivy saponin B: ivy saponin D = (12-25): (5-10): 1: (1-2), and the corresponding average inhibition rates are all higher than 77%; the saponin content ratio of spiked control group 3 is also within the range of the composition of Example 2, but the average inhibition rate is only 61.57%; the saponin content of control 1, spiked control 2, control 2, and control 3 does not meet the ratio range of the composition, and the corresponding inhibition rates are all less than 67%.

[0124] The spiked control 1 added hederaconin D, the D / B content ratio increased from 0.78 in control 1 to 1.55, the C / D content ratio decreased from 25.17 to 12.74, the total polysaccharide and total flavonoid contents did not change significantly, but the inhibition rate increased from 63.17% in control 1 to 78.11%, and the inhibition rate increased by 15%. The spiked control 2 added hederaconin C and hederaconin D, the D / B content ratio increased from 0.78 in control 1 to 3.27, the C / B content ratio increased from 19.70 to 23.37, the C / D content ratio decreased from 25.17 to 7.15, the total polysaccharide and total flavonoid contents did not change significantly, and the inhibition rate was 66.64%, which was similar to the inhibition rate of control 1.

[0125] From the comparison of saponin contents between spiked control 1 and spiked control 2, it was found that the content of hederacoside C in spiked control 2 (47.08%) increased by 2.56% compared with spiked control 1 (44.52%), the content of α-hederacoside (10.51%) decreased by 1.28% compared with spiked control 1 (11.79%), the content of hederacoside B (2.01%) decreased by 0.25% compared with spiked control 1 (2.26%), and the content of hederacoside D (6.58%) increased by 3.09% compared with spiked control 1 (3.49%). Combined with the anti-inflammatory activity results of saponin monomers in Table 1, it can be seen that the order of anti-inflammatory activity is hederacoside C>α-hederacoside>hederacoside B>hederacoside D, and the corresponding inhibition rates at a dosage concentration of 100 μg / mL are 36.87%, 33.16%, 27.06% and 22.23% respectively. The increase of hederaconin C in spiked control 2 and the decrease of α-hederaconin were substituted at a 1:1 ratio, and the increase of hederaconin C was 1.28%; the decrease of hederaconin B and the increase of hederaconin D were substituted at a 1:2 ratio, and the increase of hederaconin D was 2.59%. There was no significant change in total flavonoids and total polysaccharides. When the saponin content increased by 4%, the inhibition rate of spiked control 2 decreased from 78.11% in spiked control 1 to 66.64%. It can be seen that the content ratio of the four saponins in ivy leaf extract can achieve better anti-inflammatory effects within the specific range of spiked control 1. Combined with the saponin ratio and inhibition rate of extracts 1-3 and spiked control 1, it was found that the four saponins all met the ratio of ivy saponin C: α-ivy saponin: ivy saponin B: ivy saponin D = (12-25): (5-10): 1: (1-2), and the inhibition rate was greater than 77%, with good anti-inflammatory activity. Preferably, ivy saponin C: α-ivy saponin: ivy saponin B: ivy saponin D = (12-21): (5-9): 1: (1-1.6). In addition, the addition of standard products to make the component content index of ivy leaf extract meet the above conditions can also obtain the technical effect of good anti-inflammatory effect. Therefore, the source raw material and extraction method of ivy leaf extract can be unrestricted. Even if the content of specific saponins in the ivy leaf raw material is limited, or different extraction methods lead to different saponin content ratios, the saponin component content in the extract can meet the requirements of the scope of the present invention by adding standard products, thereby obtaining better anti-inflammatory activity. Therefore, the present invention can increase the raw material sources of ivy leaf extract; at the same time, it reduces the requirements for the saponin content in the ivy leaf medicinal material, expands the source base of the medicinal material, and reduces the production cost.

[0126] The prior art discloses a preparation method of control 2, which differs from control 1 in that it has not been treated with alkali solution. The obtained control 2 extract has a higher content of saponin C, but the crude extract has not been treated with alkali solution, and the flavonoids and polysaccharides lost during column chromatography elution are relatively high. The obtained ivy saponin C content is 61.3%, the total flavonoids content is 1.4%, and the total polysaccharide content is 1.6%, corresponding to an inhibition rate of 66.73%, which is similar to the inhibition rate of 63.17% of the control 1 extract, but significantly lower than the inhibition rates of extracts 1-3 and spiked control 1. Component analysis found that even though the total saponin content of control 2 was 79.6%, slightly higher than extracts 1-3 and spiked control 1, the total flavonoids and total polysaccharides were 1 / 3 of those of extracts 1-3 and spiked control 1. The anti-inflammatory results showed that saponins, total flavonoids, and total polysaccharides were all active ingredients of ivy leaf extracts. If the content of total flavonoids and total polysaccharides is low, the anti-inflammatory effect is not good, so the content of total flavonoids and total polysaccharides also needs to meet the range requirements of the present invention.

[0127] The spiked control 3 was added with ivy saponin C, and the C / B content ratio increased from 11.0 in the control 3 to 14.97, thus satisfying the ratio of ivy saponin C: α-ivy saponin: ivy saponin B: ivy saponin D = (12-25): (5-10): 1: (1-2). However, the corresponding inhibition rate of the spiked control 3 was 61.57%, which was close to the inhibition rate of the control 3 of 62.78%. A comprehensive comparison showed that the total flavonoid content and total polysaccharide content of the control 3 and the spiked control 3 were both less than 1%, and the total saponin content was 56.34%, which was significantly lower than that of the extracts 1-3 or the spiked control 1. It can be seen that the total flavonoid content, total polysaccharide content and total saponin content are the pharmacological index components of the ivy leaf extract. Combining the component contents of the extracts 1-3 and the spiked control 1, it was found that the anti-inflammatory effect of the ivy leaf extract was better when the total flavonoid content was greater than 4%, the total polysaccharide content was greater than 2%, and the total saponin content was greater than 70%.

[0128] Table 8 Inhibitory activity of different ivy leaf extracts on COX-2 enzyme

[0129]

[0130] Example 12: Identification of extract components

[0131] The chemical composition of extracts 1-3 and spiked control 1-3 extracts was determined, and component analysis was performed in combination with Hedera helix and Hedera sinensis medicinal materials.

[0132] 1. Test methods

[0133] 1.1 Preparation of test samples

[0134] Take 0.01 g of each of the extracts 1-3 and spiked controls 1-3 into a 1.5 mL epoxide tube, add 1 mL of 80% methanol, perform ultrasonic extraction for 1 hour, centrifuge at 10,000 rpm for 10 minutes, and transfer the supernatant to an Agilent injection bottle for later use.

[0135] Weigh 1g of Hedera helix powder and Hedera sinensis powder, make two parallel portions, add 20mL of pure water to one portion and 20mL of 80% methanol to the other portion, and perform ultrasonic extraction for 1 hour. Pass the extract through the corresponding 0.22μm microporous filter membrane, collect the filtrate, and concentrate to 2mL by centrifugation. Pass the concentrate through the SPE column, elute with methanol-water (9:1, v / v), collect the eluate, and concentrate to dryness by centrifugation. Redissolve in 1mL of methanol-water (9:1, v / v), centrifuge at 10000rpm for 10 minutes, and transfer the supernatant to an Agilent injection bottle for later use.

[0136] 1.2 Detection Method

[0137] Liquid phase conditions: chromatographic column Agilent ZORBAX Eclipase XDB-C18 (Analytical 4.6×250mm, 5-micron); column temperature 30°C; flow rate 1mL / min; UV detection wavelength 205nm; mobile phase, (A) 0.05% formic acid-water, (B) acetonitrile; gradient: 0min, 5%B; 30min, 30%B; 60min, 85%B; 65min, 95%B; 70min, 95%B.

[0138] Mass spectrometry conditions: negative ion mode, drying gas temperature 320°C; drying gas flow rate 8 L / min; nebulizer gas pressure 45 psig; sheath gas temperature 350°C; sheath gas flow rate 11 L / min; source voltage 3500 V; fragmentor voltage 175 V; skimmer voltage 65 V; primary ion range 100-1700 m / z; collision energy 10 V, 20 V, 40 V; automatic secondary acquisition, dynamic exclusion turned on.

[0139] Positive ion mode: drying gas temperature 320°C; drying gas flow rate 8 L / min; nebulizer gas pressure 45 psig; sheath gas temperature 350°C; sheath gas flow rate 11 L / min; source voltage 4000 V; fragmentor voltage 175 V; skimmer voltage 65 V; primary ion range 100-1700 m / z; collision energy 10 V, 20 V, 40 V; automatic secondary acquisition, dynamic exclusion on.

[0140] 2. Test results

[0141] The component analysis results of extracts 1-3 and controls 1-3 are shown in Table 9. The components include organic acids, flavonoids, glycosides, saponins and others, a total of 32 compounds. Among them, 10 organic acids, 2 flavonoids, 8 glycosides, 6 saponins and 6 other compounds were identified. The detection and identification of the above compounds further clarified the active ingredients of ivy leaf extract.

[0142] Comparison of the components of the six extracts revealed that nine components were detected in common in extracts 1-3 and controls 1-3; 23 components were detected in extracts 1-3 and control 1 that were different from controls 2 and 3, as shown in Table 10. The difference between spiked control 1 and spiked control 2 and control 1 was the increase in the amount of hederaconin C and hederaconin D; the difference between spiked control 3 and control 3 was the increase in the amount of hederaconin C, and there was no effect on the types of components before and after spiking.

[0143] Control 2, control 3 and spiked control 3 did not contain common distinguishing compounds, and the saponin ratio, total flavonoid content, total polysaccharide content, total saponins and extracts 1-3 and spiked control 1 were different, corresponding to poor anti-inflammatory effects.

[0144] According to the component detection results in Table 10, the anti-inflammatory effects of control 1, spiked control 1 and spiked control 2 in Table 8 show that even though the above three extracts contain common distinguishing compounds, the anti-inflammatory effect of spiked control 1 is significantly better than that of control 1 and spiked control 2. It can be seen that the saponin ratio, total flavonoid content, total polysaccharide content and total saponin content also directly affect the anti-inflammatory results.

[0145] Therefore, extracts 1-3 and spiked control 1 all contain the common distinguishing compounds in Table 10, and the corresponding saponins meet the ratio of ivy saponin C: α-ivy saponin: ivy saponin B: ivy saponin D = (12-25): (5-10): 1: (1-2). When the total flavonoid content is greater than 4%, the total polysaccharide content is greater than 2%, and the total saponin content is greater than 70%, the anti-inflammatory effect of the ivy leaf extract is better. This technical solution provides an ivy leaf extract with better anti-inflammatory effect and clearer ingredients. In addition, by detecting the above ingredients in the ivy leaf extract, it can also be confirmed whether the obtained ivy leaf extract meets the ingredient requirements.

[0146] Table 9 Components of Ivy Leaf Extract

[0147]

[0148]

[0149] In Table 9, in the * column, 1 means that the ingredient is contained in both the raw material Hedera helix and the extract, and 2 means that the ingredient is not detected in Hedera helix but is detected in the extract (it may not be detected due to the complex ingredients of the medicinal material, or it may be transformed during the extraction)

[0150] In the # column, 1 represents that the ingredient is common to both English ivy and Chinese ivy; 2 represents that the ingredient is unique to English ivy or its content is higher than that of Chinese ivy.

[0151] Table 10 Test results of different ivy leaf extract components

[0152]

[0153]

[0154] Example 13: Pharmacodynamic effects of ivy leaf extract on lipopolysaccharide (LPS)-induced acute bronchitis model in mice 1. Experimental drugs and reagents

[0155] LPS (Sigma-Aldrich (Shanghai) Trading Co., Ltd.); Prospan oral solution (produced by Engelhard Arzneimittel, batch number: 22G080A); Ambroxol hydrochloride oral solution (produced by China Resources Sanjiu (Nanchang) Pharmaceutical Co., Ltd., batch number: 2112020J); Honey-refined Chuanbei loquat paste (produced by Kyoto Ninji General Factory Co., Ltd., batch number: Y12102104); Sample of extract 3 prepared in Example 5 (prepared by Zhejiang Kangenbei Traditional Chinese Medicine Co., Ltd.).

[0156] 2. Animal grouping

[0157] After three days of adaptive feeding, SPF Balb / c mice were divided into 6 groups according to their body weight, with 10 mice in each group.

[0158] Table 11 Animal grouping

[0159] Group Modeling treat Remark Blank control group Pure water Pure water N=10 Model Group LPS Pure water N=10 Dexamethasone group LPS 2 mg / kg dexamethasone N=10 Honey-refined Chuanbei Loquat Paste LPS 5.8ml / kg Honey-refined Chuanbei loquat paste N=10 Prospan Group LPS 3.2ml / kgProspan N=10 Extract 3 groups LPS 3.11mg / kg extract 3 N=10

[0160] 3. Route and time of administration

[0161] Oral gavage, 0.2 ml / 10 g body weight for 3 consecutive days.

[0162] 4. Model replication

[0163] Healthy mice were taken and 6 mg / ml LPS saline solution was dripped into the nasal cavity at 10 mg / kg using a pipette for 3 consecutive days, and the mice were killed after 5 days. The drug was administered once a day, two days before modeling, and continued until modeling.

[0164] 5. Index detection

[0165] The animal serum was collected 1 hour after the last administration to detect the changes of inflammatory factor TNF-α.

[0166] 6. Statistical methods

[0167] All data were expressed as Mean±SD. The differences between each group and the model group were analyzed using t-test, with p<0.05 considered statistically significant.

[0168] 7. Experimental results

[0169] As shown in Table 12, the serum TNF-α of the mice in the model group increased at the end of administration, which was significantly different from that in the control group (P<0.01); compared with the model group, the drug groups were able to reduce the serum TNF-α at the end of administration, and 2mg / kg of dexamethasone acetate could reduce the level of TNF-α in serum, which was significantly different from that in the model group (P<0.01); 5.8ml / kg of Kyoto Nien Jiom Honey Refined Chuanbei Loquat had no difference compared with the model group, 3.2ml / kg of Prospan could reduce the level of TNF-α in serum, which was significantly different from that in the model group (P<0.05); 3.11mg / kg of extract 3 was significantly different from that in the model group (P<0.05). The experimental results showed that extract 3 could effectively inhibit the growth of inflammatory factors in acute bronchitis in mice induced by LPS, had a therapeutic effect, and its anti-inflammatory effect was better than that of the Prospan group.

[0170] Table 12 Effect of ivy leaf extract on serum TNF-α in mice with acute bronchitis (n=10, Mean±SD)

[0171]

[0172] Note: **P<0.01 vs model group; *P<0.05 vs model group

[0173] Example 14: Study on the expectorant effect of ivy leaf extract on mouse expectorant model (phenol red method)

[0174] 1. Experimental drugs and reagents

[0175] Phenol red (GENERAL-REAGENT); ELISA reader (Thermo); drug sources are as shown in Example 13.

[0176] 2. Animal grouping

[0177] After three days of adaptation, 60 SPF ICR mice were randomly divided into 6 groups according to body weight, with 10 mice in each group. The groups are shown in Table 13:

[0178] Table 13 Animal grouping

[0179] Group Modeling treat Remark Blank control group Pure water Pure water N=10 Model Group 5% phenol red Pure water N=10 Ambroxol hydrochloride oral solution group 5% phenol red 2.57ml / kg ambroxol hydrochloride oral solution N=10 Honey-refined Chuanbei Loquat Paste 5% phenol red 5.8ml / kg Honey-refined Chuanbei loquat paste N=10 Prospan Group 5% phenol red 3.2ml / kgProspan N=10 Extract 3 groups 5% phenol red 3.11mg / kg extract 3 N=10

[0180] 3. Route and time of administration

[0181] The drug was administered by oral gavage once a day for 3 consecutive days, with a dosing volume of 0.2 ml / 10 g body weight.

[0182] 4. Model replication

[0183] 30 minutes after the last administration of the mice, 0.1 ml / 10 g of 5% phenol red solution was injected intraperitoneally. The animals were killed 30 minutes later, the trachea was dissected and separated, and a flattened No. 7 needle was inserted into the trachea 0.3 cm, tied with silk thread, and 0.5 ml of 5% sodium bicarbonate solution was drawn with a 1 ml syringe. The respiratory tract was irrigated back and forth through the needle for 3 times, and the irrigating fluid was drawn out for the last time and injected into a test tube. The above operation was repeated 3 times, and about 1 ml of irrigating fluid was drawn, placed in a test tube, centrifuged at 1500 rpm for 5 minutes, and 150 μl of supernatant was drawn into a 96-well plate.

[0184] 5. Index detection

[0185] The OD value at 546 nm was measured with an enzyme-labeled instrument and adjusted to zero with 5% sodium bicarbonate solution.

[0186] 6. Statistical methods

[0187] All data were expressed as Mean±SD. The t-test was used to analyze the significance among groups. The differences between each group and the model group were tested, and p<0.05 was considered statistically significant.

[0188] 7. Experimental results

[0189] As shown in Table 14, 3.2ml / kg Prospan can increase the phenol red secretion of mouse trachea, which is significantly different from the model group (P<0.05); 2.57ml / kg ambroxol hydrochloride oral solution has a certain promoting effect on the phenol red secretion of mouse trachea, but there is no difference compared with the model group (P>0.05); 3.11mg / kg extract 3 can increase the phenol red secretion of mouse trachea, which is significantly different from the model group (P<0.05); 5.8ml / kg honey refined Chuanbei loquat paste group has no obvious promoting effect. It can be seen that extract 3 can increase the phenol red secretion of female mouse trachea and has a certain expectorant effect.

[0190] Table 14 Expectorant effect results of ivy leaf extract

[0191] Group dose OD value Blank control group / 0.159±0.054 Model Group / 0.180±0.042 Ambroxol hydrochloride oral solution group 2.57ml / kg 0.224±0.097 Honey-refined Chuanbei Loquat Paste 5.8ml / kg 0.172±0.040 Prospan Group 3.2ml / kg 0.224±0.044* Extract 3 groups 3.11mg / kg 0.229±0.038*

[0192] Note: *P<0.05vs model group

[0193] Example 15: Study on the antitussive effect of ivy leaf extract on mouse antitussive model (ammonia method)

[0194] 1. Experimental drugs and reagents

[0195] Ammonia water (Sinopharm Chemical Reagent Co., Ltd.); Dextromethorphan hydrobromide tablets (Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd.); the sources of the drugs are as shown in Example 13.

[0196] 2. Animal grouping

[0197] After three days of adaptive feeding, 50 SPF ICR female mice were divided into 5 groups according to their weight, with 10 mice in each group. The groups are shown in Table 15.

[0198] Table 15 Animal grouping

[0199] Group Modeling treat Remark Model Group 12% ammonia water Pure water N=10 Dextromethorphan Hydrobromide Tablets 12% ammonia water 1.03 tablets / kg Dextromethorphan Hydrobromide Tablets N=10 5.8ml / kg honey refined Chuanbei loquat paste group 12% ammonia water 5.8ml / kg Honey-refined Chuanbei loquat paste N=10 3.2 ml / kg Prospan group 12% ammonia water 3.2ml / kgProspan N=10 Extract 3 groups 12% ammonia water 3.11mg / kg extract 3 N=10

[0200] 3. Route and time of administration

[0201] Oral gavage, 0.2 ml / 10 g body weight for 3 consecutive days.

[0202] 4. Model replication

[0203] One hour after the last administration, the mice were placed in a YLS-8A multifunctional cough and wheeze inducing instrument and atomized with 12% ammonia for 10 seconds. The cough latency and the number of coughs within 2 minutes were observed and recorded.

[0204] 5. Index detection

[0205] Cough latency period, the total number of coughs within 2 minutes.

[0206] 6. Statistical methods

[0207] All data were expressed as Mean±SD. The differences between each group and the model group were analyzed by t-test, with p<0.05 considered statistically significant.

[0208] 7. Experimental results

[0209] As shown in Table 16, mice were given 3.2 ml / kg Prospan, 1.03 tablets / kg of dextromethorphan hydrobromide, 5.8 ml / kg honey refined Chuanbei loquat paste, and 3.11 mg / kg extract 3 for 3 consecutive days to prolong the cough latency of mice, which was significantly different from the model group (P<0.01). According to the Prospan oral solution instructions, the ratio of ivy dry extract to crude drug is 5 to 7.5:1, and the average 1 mg of ivy dry extract contains 6.25 mg of crude drug. The oral solution contains 7 mg of ivy dry extract per milliliter, and it can be inferred that 1 mL of oral solution contains 43.75 mg of ivy medicinal materials. The dosage of 3.2 ml / kg of Prospan oral solution corresponds to the amount of crude drug taken (calculated by mice) of 3.2*43.75=140 mg / kg. The yield of extract 3 is 3.9%, and the corresponding crude drug dosage is dose / yield, that is, 3.11 / 3.9%=79.74 mg / kg. The experimental results show that extract 3 can prolong the cough latency of mice and has a certain antitussive effect, and the corresponding crude drug dosage is less than that of the Prospan group.

[0210] Table 16 Effect of ivy leaf extract on cough latency in mice (n=10, Mean±SD)

[0211] Group dose Cough latency period(s) Model Group / 20.9±5.9 Dextromethorphan Hydrobromide Tablets 1.03 pieces / kg 33.3±9.7** Honey-refined Chuanbei Loquat Paste 5.8ml / kg 40.8±10.5** Prospan Group 3.2ml / kg 38.6+8.3** Extract 3 groups 3.11mg / kg 29.2±7.1**

[0212] Note: **P<0.05vs model group

[0213] As shown in Table 17, mice were given 3.2 ml / kg Prospan, 1.03 tablets / kg dextromethorphan hydrobromide, 5.8 ml / kg honey refined Chuanbei loquat paste, and 3.11 mg / kg extract 3 for 3 consecutive days, which can reduce the number of coughs in mice, and there is a significant difference compared with the model group (P<0.01). The experimental results show that extract 3 can reduce the number of coughs in mice, has a certain antitussive effect, and the corresponding raw drug amount is less than that of the Prospan group.

[0214] Table 17 Effect of ivy leaf extract on the total number of coughs in mice within 2 minutes (n=10, Mean±SD)

[0215] Group dose frequency Model Group / 27.9±4.5 Dextromethorphan Hydrobromide Tablets 1.03 pieces / kg 17.1±6.2** Honey-refined Chuanbei Loquat Paste 5.8ml / kg 17.9±5.3** Prospan Group 3.2ml / kg 17.1±3.3** Extract 3 groups 3.11mg / kg 20.7±4.6**

[0216] Note: **P<0.05vs model group.

Claims

1. An ivy saponin composition, characterized in that The hedera saponin composition comprises hedera saponin C, α-hedera saponin, hedera saponin B and hedera saponin D, wherein the mass ratio of hedera saponin C, α-hedera saponin, hedera saponin B and hedera saponin D is 12-25:5-10:1:1-2.

2. The ivy saponin composition according to claim 1, characterized in that The mass ratio of the hedera saponin C to the hedera saponin D is 8-16:

1.

3. The ivy saponin composition according to claim 1, characterized in that The mass ratio of the hederaconin C, α-hederaconin, hederaconin B and hederaconin D is 16-25:5-7:1:1-2.

4. The ivy saponin composition according to claim 1, characterized in that The mass ratio of the hederaconin C, α-hederaconin, hederaconin B and hederaconin D is 12-16:7-10:1:

1.

5. An ivy leaf extract, characterized in that The ivy leaf extract comprises hederacoside C, α-hederacoside, hederacoside B and hederacoside D, wherein the mass ratio of hederacoside C, α-hederacoside, hederacoside B and hederacoside D is 12-25:5-10:1:1-2; in the extract, the content of hederacoside C is not less than 25%, the content of total flavonoids is not less than 4%, the content of total polysaccharides is not less than 2%, and the content of total saponins in the ivy leaf extract is not less than 70%.

6. The ivy leaf extract according to claim 5, characterized in that The mass ratio of the hederaconin C, α-hederaconin, hederaconin B and hederaconin D is 12-21:5-9:1:1-1.

6.

7. The ivy leaf extract according to claim 5, characterized in that The content of α-hedera saponin in the extract is not less than 10%.

8. The ivy leaf extract according to claim 5, characterized in that In the extract, the content of hederacoside C is not less than 30%, the content of hederacoside D is not less than 2%, and the content of hederacoside B is not less than 2%.

9. The ivy leaf extract according to claim 5, characterized in that The ivy leaf extract further comprises organic acid compounds, flavonoid compounds, saponin compounds, glycoside compounds and other compounds, wherein the organic acid compounds comprise one or more of quinic acid, neochlorogenic acid, cryptochlorogenic acid, asiatic acid, madecassic acid, 3-O-sulfated echinocystic acid and 3-O-sulfated oleanolic acid; The flavonoid compound includes one or both of isoquercetin and nicotinic acid glycoside; The glycoside compound includes one or more of 3-O-β-D-pyranoglucopyranoside butyrate ethyl ester, (E)-4-O-β-D-pyranoglucopyranosyl-p-coumaric acid, 3-methylbut-2-enyl[β-D-furanoseyl-(1→6)]-β-D-pyranoglucopyranoside, epimedin F2, myresculoside, cincalciferol B19-O-β-D-pyranoglucopyranoside, and nomiline 17-β-D-pyranoglucopyranoside; The saponin compound includes one or two of β-hedera saponin and cyperus saponin A; The other compounds include one or more of 1-O-galloylglycerol, salidroside D, 3-methoxy-4-hydroxyphenol 1-O-[β-D-furanose syl-(1→6)]-β-D-pyranoglucoside, icariin B5, cinnamon acid H and cimicifuga epoxyglycoside.

10. The ivy leaf extract according to claim 9, characterized in that The ivy leaf extract includes α-hedera saponin, hedera saponin B, hedera saponin C and hedera saponin D, and one or more of the following compounds: quinic acid, neochlorogenic acid, cryptochlorogenic acid, asiatic acid, madecassic acid, 3-O-sulfated echinococcal acid, 3-O-sulfated oleanolic acid, 3-O-β-D-pyranoglucopyranoside butyric acid ethyl ester, (E)-4-O-β-D-pyranoglucopyranosyl-p-coumaric acid, myresculoside, β-hedera saponin, salidroside A, salidroside D, 3-methoxy-4-hydroxyphenol 1-O-[β-D-furanose syl-(1→6)]-β-D-pyranoglucopyranoside, antler acid H and cimicifuga epoxy alcohol glycoside.

11. The ivy leaf extract according to claim 10, characterized in that The ivy leaf extract comprises chlorogenic acid, shikimic acid, 3-O-p-coumarylquinic acid, nicotinic acid, esculin, α-hedera saponin, hedera saponin B, hedera saponin C and hedera saponin D.

12. Use of the ivy saponin composition according to any one of claims 1 to 4 or the ivy leaf extract according to any one of claims 5 to 11 in the preparation of a drug for treating or preventing acute bronchitis.

13. Use of the ivy saponin composition according to any one of claims 1 to 4 or the ivy leaf extract according to any one of claims 5 to 11 in the preparation of expectorant and antitussive drugs.

14. A drug for treating or preventing acute bronchitis, characterized in that The drug comprises the ivy saponin composition according to any one of claims 1 to 4 or the ivy leaf extract according to any one of claims 5 to 11.

15. An expectorant and antitussive drug, characterized in that The drug comprises the ivy saponin composition according to any one of claims 1 to 4 or the ivy leaf extract according to any one of claims 5 to 11.

Citation Information

Cited By

  • Hederasaponin composition, hedera leaf extract comprising composition, and use thereof

    WO2026045348A1